Key facts
- Collate’s last known valuation is $140.0M (Jan 2025).
- It has raised $30.0M; the latest was Seed Round ($30.0M) in Jan 2025.
- Notable investors include Y Combinator, First Round Capital, Redpoint Ventures, Conviction Partners, Parcel B.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Collate
- ·The full record, as it builds
Funding rounds
No funding rounds for Collate are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Collate
Developer of an AI-based life sciences documentation platform designed to automate the documentation processes that slow down drug and medical device development. The company's platform uses AI to create and streamline paperwork for diagnostic, medical device, and drug development companies to life-saving innovations to patients, enabling life science companies to automate extensive documentation for every stage of their operations, from research and clinical trials to manufacturing and labeling.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 8
- Website
- collate.com/
- Ownership
- Privately Held (backing)
Collate doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Collate shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Collate in its N-PORT filings yet. We sweep new filings monthly.